Therapeutic heterocyclic compounds

US6812225B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Edward Pierson · Wilmington, US
• Daniel Sohn · Gately Drive, SE
• Markus Haeberlein · Wellesley, US
• Timothy Davenport · New Castle, US
• Marc Chapdelaine · Wilmington, US
• Carey Horchler · Wayne, US
• John McCauley · Wilmington, US

Key dates

• Filing date: Jan 16, 2002
• Grant date: Nov 2, 2004
• Expiry date: Jan 27, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.